Cancer Immunotherapy via Synergistic Coactivation of Myeloid Receptors CD40 and Dectin-1

By cotargeting myeloid activation molecules, scientists leveraged the myeloid compartment as a therapeutic vulnerability in mouse models of pancreatic cancer.